Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 9, 2012, Pages 1309-1313

  Sasada, Tetsuro ^a   Noguchi, Masanori ^b   Yamada, Akira ^b   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

Advanced cancer; Biomarker; Cytotoxic T lymphocytes; Inflammation; Peptide vaccine; Personalized vaccine

Indexed keywords

ALBUMIN; ANTIBODY; C REACTIVE PROTEIN; CANCER VACCINE; ESTRAMUSTINE PHOSPHATE; FREUND ADJUVANT; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A26 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 6; PEPTIDE VACCINE; TOCILIZUMAB; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALBUMIN BLOOD LEVEL; CANCER CELL; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; GLIOBLASTOMA; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MONOTHERAPY; NOTE; OVERALL SURVIVAL; PEPTIDE ANALYSIS; PERSONALIZED MEDICINE; PERSONALIZED PEPTIDE VACCINATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; VACCINATION;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINES, SUBUNIT;

EID: 84866976265     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20988     Document Type: Note

References (27)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7; PMID:1840703; http://dx.doi.org/10.1126/science.1840703.
2. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613; PMID:22395641; http://dx.doi.org/10.1093/ jnci/djs033.
3. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11:805-12; PMID:22020206; http://dx.doi.org/10.1038/nrc3153.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
6. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer 2010; 46:1514-9; PMID:20413296; http://dx.doi.org/10.1016/j.ejca.2010.03. 013.
7. Eggermont AM. Therapeutic vaccines in solid tumours: can they be harmful? Eur J Cancer 2009; 45:2087-90; PMID:19477117; http://dx.doi.org/10.1016/j.ejca. 2009.05.004.
8. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737.
9. Chen W, McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res 2006; 95:203-47; PMID:16860659; http://dx.doi.org/10.1016/S0065-230X(06) 95006-4.
10. Mochizuki K, Sato Y, Tsuda N, Shomura H, Sakamoto M, Matsuura K, et al. Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004; 25:121-31; PMID:15201997.
11. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486.
12. Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97:970-6; PMID:16984371; http://dx.doi.org/10.1111/j.1349-7006.2006.00272.x.
13. Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009; 39:73-80; PMID:19015149; http://dx.doi.org/10.1093/jjco/hyn132.
14. Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, et al. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncol Rep 2011; 25:57-62; PMID:21109957.
15. Whiteside TL. Immune monitoring of clinical trials with biotherapies. Adv Clin Chem 2008; 45:75-97; PMID:18429494; http://dx.doi.org/10.1016/S0065- 2423(07)00004-2.
16. Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10:1266-79; PMID:20935522.
17. Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004; 64:535-45; PMID:15370458; http://dx.doi.org/10.1080/00365510410007008.
18. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59:1001-9; PMID:20146063; http://dx.doi.org/10.1007/s00262-010-0822-4.
19. Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen - A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29:337-44; PMID:21149665; http://dx.doi.org/10.1200/JCO.2010. 29.7499.
20. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011; 60:433-42; PMID:21221967; http://dx.doi.org/10.1007/s00262-010-0960-8.
21. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388-97; PMID:20826737; http://dx.doi.org/10.1093/jnci/djq310.
22. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118:499-509; PMID:21531979; http://dx.doi.org/10.1182/blood-2011-01-325266.
23. López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 2009; 27:945-52; PMID:19139436; http://dx.doi.org/10.1200/ JCO.2008.18.0794.
24. Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, et al. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 2011; PMID:22071976.
25. Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 2012; 40:1492-500; PMID:22307435.
26. Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status, and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012; 3:463-9.
27. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30:1005-14; PMID:22355058; http://dx.doi.org/10.1200/JCO.2010.31.8907.